Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.36 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21174476 | 0.87 | BTK (0.36) | ADORA1BTKPBKALDH1A1ADORA3 | |
| SCHEMBL21174215 | 0.84 | ADORA1 (0.38) | ADORA1BTKPBKADORA3ADORA2B | |
| SCHEMBL21174066 | 0.81 | ADORA1 (0.36) | ADORA1BTKPBKADORA3ADORA2B | |
| SCHEMBL21174272 | 0.80 | NPC1 (0.44) | ALDH1A1 | |
| SCHEMBL21174078 | 0.77 | PBK (0.38) | ADORA1BTKPBKALDH1A1ADORA2B | |
| SCHEMBL31456923 | 0.75 | ALDH1A1 (0.46) | ADORA1BTKALDH1A1ADORA2BADORA2A | |
| SCHEMBL27374784 | 0.75 | ALDH1A1 (0.46) | ADORA1BTKALDH1A1ADORA2BADORA2A | |
| SCHEMBL21174309 | 0.74 | PBK (0.38) | ADORA1BTKPBKADORA2BADORA2A | |
| SCHEMBL21174152 | 0.74 | ALDH1A1 (0.36) | ADORA1BTKPBKALDH1A1ADORA3 | |
| SCHEMBL21174228 | 0.74 | PBK (0.40) | ADORA1BTKPBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | PRSS8, PRSS1, PRSS2 | ADORA1 4707/4885BTK 3904/4885PBK 4535/4885 |
| US-10774083-B2 | Heterocyclic amide compound | PRSS8, PRSS1, PRSS2 | ADORA1 4707/4885BTK 3904/4885PBK 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.